echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Hengrui Pharmaceuticals Ivabradine Hydrogen Sulfate Sustained-Release Tablets Approved for Clinical Trial

    Hengrui Pharmaceuticals Ivabradine Hydrogen Sulfate Sustained-Release Tablets Approved for Clinical Trial

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 20, Hengrui Medicine issued an announcement stating that it had recently received approval from the State Food and Drug Administration to issue a "Drug Clinical Trial Approval Notice" for ivabradine hydrogen sulfate sustained-release tablets, and clinical trials will be launched in the near future.

    Indications: This product is suitable for NYHAII~IV chronic heart failure patients with sinus rhythm, heart rate ≥70 beats/min, and cardiac systolic dysfunction.
    It is used in combination with standard treatment including β-blockers, or used When contraindicated or cannot tolerate β-blocker treatment.

    Ivabradine is a pure heart rate-lowering drug, which reduces the heart rate by selectively and specifically inhibiting the If current of cardiac pacing.
    Ivabradine was originally made into tablets in the form of hydrochloride, and it was first listed in France in October 2005.
    The application company was French Servier with the trade name Procoralan/Corlentor; it was listed in the United States in April 2015.
    The applicant company is Amgen of the United States, the trade name is Corlanor; in 2015, the State Food and Drug Administration approved the import of French Servier Ivabradine hydrochloride tablets (trade name: Corlanor).

    Upon inquiry, similar products in Europe, such as Ivabradine Anpharm and Ivabradine Accord, have been approved.
    At present, only Les Laboratoires Servier's ivabradine hydrochloride tablets are on the market.
    Hengrui Medicine has developed a single and stable ivabradine bisulfate, and there is no sustained-release ivabradine bisulfate tablet on the market at home and abroad.

    Upon inquiry, the global sales of ivabradine tablets in 2019 were US$379 million.
    Up to now, Hengrui Pharmaceuticals has invested approximately RMB 50.
    94 million in research and development related projects related to ivabradine hydrogen sulfate.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.